Financial Snapshot

Revenue
$33.74M
TTM
Gross Margin
Net Earnings
-$78.00M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1132.75%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$201.0M
Q3 2024
Cash
Q3 2024
P/E
-3.961
Nov 29, 2024 EST
Free Cash Flow
-$91.65M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021
Revenue $33.49M $4.931M $2.002M
YoY Change 579.21% 146.3%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021
Revenue $33.49M $4.931M $2.002M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

No data

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $13.91M $20.78M $12.86M
YoY Change -33.04% 61.5%
% of Gross Profit
Research & Development $50.25M $43.98M $42.41M
YoY Change 14.25% 3.71%
% of Gross Profit
Depreciation & Amortization $2.266M $1.158M $248.0K
YoY Change 95.68% 366.94%
% of Gross Profit
Operating Expenses $64.16M $64.76M $55.27M
YoY Change -0.92% 17.16%
Operating Profit
YoY Change

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $2.535M $1.294M $0.00
YoY Change 95.9%
% of Operating Profit
Other Income/Expense, Net -$512.0K -$200.0K -$18.55M
YoY Change 156.0% -98.92%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

No data

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$28.65M -$58.74M -$71.83M
YoY Change -51.22% -18.22%
Income Tax $72.00K $53.00K
% Of Pretax Income
Net Earnings -$28.72M -$58.79M -$71.83M
YoY Change -51.15% -18.15%
Net Earnings / Revenue -85.75% -1192.21% -3587.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.23 -$2.53 -$3.09

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $76.97M $102.5M $160.9M
YoY Change -24.93% -36.29%
Cash & Equivalents $53.50M $102.5M $160.9M
Short-Term Investments $23.47M $0.00
Other Short-Term Assets $1.092M $1.619M $896.0K
YoY Change -32.55% 80.69%
Inventory
Prepaid Expenses
Receivables $1.034M $525.0K $468.0K
Other Receivables $724.0K $0.00 $0.00
Total Short-Term Assets $79.82M $104.7M $162.3M
YoY Change -23.74% -35.5%
Property, Plant & Equipment $24.64M $27.62M $4.078M
YoY Change -10.77% 577.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $650.0K $762.0K $3.561M
YoY Change -14.7% -78.6%
Total Long-Term Assets $25.29M $28.38M $7.639M
YoY Change -10.87% 271.5%
Total Assets $105.1M $133.1M $169.9M
YoY Change
Accounts Payable $614.0K $1.096M $1.444M
YoY Change -43.98% -24.1%
Accrued Expenses $11.61M $13.64M $10.57M
YoY Change -14.85% 29.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.23M $25.63M $19.31M
YoY Change -52.28% 32.74%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $38.49M $31.71M $23.07M
YoY Change 21.37% 37.48%
Total Long-Term Liabilities $38.49M $31.71M $23.07M
YoY Change 21.37% 37.48%
Total Liabilities $50.72M $57.34M $42.37M
YoY Change -11.55% 35.32%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $308.96 Million

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 82 full-time employees. The company went IPO on 2024-07-19. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The firm's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Industry: Biological Products, (No Diagnostic Substances) Peers: HERON THERAPEUTICS, INC. /DE/ Tectonic Therapeutic, Inc. Biomea Fusion, Inc. Design Therapeutics, Inc. PRECIGEN, INC. Poseida Therapeutics, Inc. Prelude Therapeutics Inc Cartesian Therapeutics, Inc.